Eocene Ltd. (EOCN)
3.54
-0.08
(-2.21%)
USD |
NASDAQ |
Oct 09, 16:00
3.51
-0.03
(-0.85%)
Pre-Market: 20:00
Eocene Net Income (Quarterly) : -2.723M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -2.723M |
| March 31, 2026 | -1.91M |
| December 31, 2025 | -4.818M |
| September 30, 2025 | -1.892M |
| June 30, 2025 | -2.495M |
| March 31, 2025 | -1.104M |
| December 31, 2024 | -3.209M |
| September 30, 2024 | -1.914M |
| June 30, 2024 | -1.119M |
| March 31, 2024 | -1.275M |
| December 31, 2023 | -2.016M |
| September 30, 2023 | -1.473M |
| June 30, 2023 | -1.593M |
| March 31, 2023 | -1.83M |
| December 31, 2022 | -2.639M |
| September 30, 2022 | -5.35M |
| June 30, 2022 | -3.734M |
| March 31, 2022 | -6.143M |
| December 31, 2021 | -7.452M |
| September 30, 2021 | -7.714M |
| June 30, 2021 | -8.396M |
| March 31, 2021 | -8.905M |
| December 31, 2020 | -10.28M |
| September 30, 2020 | -6.905M |
| June 30, 2020 | -5.526M |
| Date | Value |
|---|---|
| March 31, 2020 | -6.063M |
| December 31, 2019 | -8.286M |
| September 30, 2019 | -4.514M |
| June 30, 2019 | -4.169M |
| March 31, 2019 | -3.492M |
| December 31, 2018 | -3.706M |
| September 30, 2018 | -0.959M |
| June 30, 2018 | -2.685M |
| March 31, 2018 | -2.506M |
| December 31, 2017 | -3.644M |
| September 30, 2017 | -2.801M |
| June 30, 2017 | -2.692M |
| March 31, 2017 | -3.162M |
| December 31, 2016 | -4.826M |
| September 30, 2016 | -3.832M |
| June 30, 2016 | -4.311M |
| March 31, 2016 | -3.984M |
| December 31, 2015 | -3.205M |
| September 30, 2015 | -2.60M |
| June 30, 2015 | -2.354M |
| March 31, 2015 | -2.463M |
| December 31, 2014 | -1.979M |
| September 30, 2014 | -3.206M |
| June 30, 2014 | -1.757M |
| March 31, 2014 | -2.161M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| BioLineRx Ltd. | -4.414M |
| XTL Biopharmaceuticals Ltd. | -- |
| Kamada Ltd. | 9.262M |
| Can-Fite BioPharma Ltd. | -- |
| Revium Recovery, Inc. | -0.584M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 2.723M |
| EPS Diluted (Quarterly) | -2.860 |
| Enterprise Value | -7.716M |
| Earnings Yield | -390.0% |
| Normalized Earnings Yield | -343.50 |